The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Pooled analysis data from EPCORE NHL-2: epcoritamab plus platinum salvage in R/R DLBCL
Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, presents pooled results from arms 4 and 10 of the EPCORE NHL-2 study (NCT04663347), which investigated the efficacy of epcoritamab plus platinum-based salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Dr Karimi highlights favorable overall and complete response rates with the addition of epcoritamab, even in a high-risk patient population, suggesting that this approach may remain relevant in the current era of CAR T-cell therapy. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
